Barinthus Biotherapeutics PLC

Barinthus Biotherapeutics PLC announces successful shareholder votes at its 2026 Annual General Meeting and secures an extended deadline until December 28, 2026, to regain Nasdaq's minimum bid price requirement.

Barinthus Biotherapeutics plc announces overwhelming shareholder approval for its Scheme of Arrangement, paving the way for a significant corporate transaction.

Barinthus Bio announced Q1 2026 financial results, highlighting progress on its merger with Clywedog Therapeutics and the ongoing Phase 1 AVALON trial for VTP-1000 in celiac disease.

Barinthus Biotherapeutics has appointed Douglas Swirsky as Chief Financial Officer and principal accounting officer, effective May 1, 2026.

Barinthus Biotherapeutics plc announced that Gemma Jones will step down as Principal Accounting Officer, effective April 30, 2026.

Barinthus Biotherapeutics announced its 2025 financial results, progress in its celiac disease trial, and reaffirmed its planned merger with Clywedog Therapeutics, expected to close in Q2 2026.

Barinthus Biotherapeutics plc reported a significantly reduced net loss for the first quarter of 2026, driven by lower operating expenses, alongside progress in its merger with Clywedog Therapeutics.

Barinthus Biotherapeutics reported a net loss of $14.6 million for Q3 2025, continued progress in its VTP-1000 celiac disease trial, and detailed its pending all-stock merger with Clywedog Therapeutics.

Barinthus Biotherapeutics PLC reported increased net losses for Q2 and H1 2025, driven by foreign exchange losses and professional fees, despite reduced R&D spending due to a strategic pipeline reprioritization towards immunology and inflammation.

Barinthus Biotherapeutics reports a net loss for Q1 2025 while strategically prioritizing its immunology and inflammation pipeline.

Barinthus Biotherapeutics PLC reported its third quarter 2024 financial results, highlighted by a significant increase in revenue due to a milestone payment, while also providing updates on its clinical pipeline and operational activities.

Barinthus Biotherapeutics reported a net loss of $32.5 million for the first half of 2024, while focusing on key pipeline programs.

Barinthus Biotherapeutics plc announced a definitive all-stock merger agreement with Clywedog Therapeutics, Inc., refocusing its pipeline on immunology and inflammation while reporting increased net losses and a Nasdaq listing deficiency.

Barinthus Biotherapeutics plc files its annual report on Form 10-K, highlighting pipeline prioritization and financial results for the year ended December 31, 2024.

Barinthus Bio's 2023 annual report highlights significant progress in its clinical pipeline, strategic partnerships, and financial objectives, positioning the company for future growth.

Barinthus Biotherapeutics and Clywedog Therapeutics have amended their merger agreement, adjusting exchange ratios and minimum cash requirements due to unexpected U.S. federal government shutdowns.

Barinthus Biotherapeutics and Clywedog Therapeutics announce an all-stock merger to create a combined company focused on metabolic and autoimmune diseases, operating as Clywedog Therapeutics, Inc.

Barinthus Biotherapeutics and Clywedog Therapeutics announce an all-stock merger to create a combined company focused on metabolic and autoimmune diseases, with Clywedog stockholders owning approximately 66%.

Barinthus Biotherapeutics plc Director Alex Hammacher was granted 20,174 share options with an exercise price of $1, aligning his interests with long-term shareholder value.

Barinthus Biotherapeutics plc. Director Robin Wright was granted 20,174 share options with an exercise price of $1, vesting by June 2026 or the next annual meeting, as disclosed in a recent SEC Form 4 filing.

Barinthus Biotherapeutics plc. Director Pierre A. Morgon was granted 20,174 share options with an exercise price of $1, aligning his interests with shareholders.

Barinthus Biotherapeutics has issued its proxy statement for the 2026 Annual General Meeting to be held on July 2, 2026.

Barinthus Biotherapeutics PLC announces its 2025 Annual Meeting and provides details on how shareholders can access proxy materials and vote.

Barinthus Biotherapeutics announces its 2025 Annual General Meeting to be held on June 10, 2025, in London.

Barinthus Biotherapeutics PLC has filed a definitive proxy statement with the SEC.

Barinthus Biotherapeutics announces its Annual General Meeting to be held on May 10, 2024, in London, addressing key resolutions including director re-elections and auditor appointments.

International Generosity Foundation Trust reports beneficial ownership of 2,734,189 shares, representing 6.7% of Barinthus Biotherapeutics plc's common stock, acquired for investment and charitable purposes.

Frank W. Cawood has filed an amended Schedule 13G, disclosing a beneficial ownership of 8.4% of Barinthus Biotherapeutics Plc's American Depositary Shares as of December 31, 2024.